New drug aims to stop dangerous gut infection from returning

NCT ID NCT05330182

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests an experimental drug called LMN-201 to see if it can prevent C. difficile infection from coming back after standard antibiotic treatment. About 375 adults with a recent C. diff infection will receive either LMN-201 or a placebo. The main goal is to see if more people stay infection-free with LMN-201.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baptist Health Research

    Lexington, Kentucky, 40503, United States

  • Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC

    Annandale, Virginia, 22003, United States

  • Gastroenterology Center of Connecticut

    Hamden, Connecticut, 06518, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • IMA Clinical Research

    Mount Airy, North Carolina, 27030, United States

  • Kaiser Permanente

    Escondido, California, 90027, United States

  • Kaiser Permanente-Mid Atlantic

    Springfield, Virginia, 22015, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic - Rochester

    Rochester, Minnesota, 55905, United States

  • Metro Infectious Disease Consultants, LLC

    Burr Ridge, Illinois, 60527, United States

  • UW Health University Hospital

    Madison, Wisconsin, 53792, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

  • University of Virginia School of Medicine

    Charlottesville, Virginia, 22903, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.